EMBECTA CORP
Embecta Corp. is a global diabetes care company. It is focused on providing solutions to people living with diabetes. It has a portfolio of products, including a range of pen needles, syringes and safety injection devices, which are complemented by its digital application designed to assist people with managing their diabetes. Its pen needles are sterile, designed to be used in conjunction with pen injectors that inject insulin or other diabetes medications. It sells safety pen needles, which have shields on both ends of the cannula that automatically deploy after the injection to help prevent needlestick exposure and injury during injection and disposal. In addition to pen needles, it sells sterile, single-use insulin syringes, which are used to inject insulin drawn from insulin vials. It has clearance from the FDA for its proprietary disposable insulin delivery system, which is indicated for adults who require insulin to manage diabetes, including both type 1 (T1D) and type 2 (T2D).
Stock Performance Snapshot
Analyst Rating
Analysts recommend holding Embecta Corp's stock with a target price of $23, indicating potential growth.
Financial Health
Embecta Corp is performing well, showing strong revenue and cash generation, with healthy profit margins.
Dividend
EMBECTA CORP's dividend yield of 4.89% offers a solid return for dividend-seeking investors. If you invested $1000 you would be paid $48.90 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring EMBC
At-Home Treatment Revolution | FDA Approval Impact
The FDA's approval of an injectable, at-home version of Eisai and Biogen's Alzheimer's drug signals a major shift in chronic disease management. This creates an investment opportunity in companies that develop advanced drug delivery systems and support at-home patient care.
Published: September 1, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Diabetes device focus
The company operates in a steady, necessity-driven market where innovation and product reliability can support growth, though competitive pressure may affect returns.
Global market opportunity
Rising prevalence of diabetes worldwide can expand addressable markets, but regulatory and reimbursement differences across regions add complexity and risk.
Execution matters most
Manufacturing scale, regulatory milestones and supply‑chain resilience drive outcomes; investors should weigh these operational factors alongside financial metrics.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Abbott Laboratories
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
Thermo Fisher Scientific, Inc.
Thermo Fisher provides a range of services and products that help customers advance their research, solve complex analytical challenges, improve patient diagnostics, and increase laboratory productivity.
Intuitive Surgical, Inc.
A healthcare company that develops, manufactures, and markets robotic-assisted surgical systems for procedures in multiple specialties
